I still say he is sitting on a mountain of Discarded stems. Those assets are the future of the company imo. You can't become a pharma without those discarded stems. The BioCordcell SA contract has the language for creditors to take possession of the stem after the 90th day. I presented the Viacell SEC filing that states to manufacturer the drug the plan then involved a public bank. CBAI enjoys a public-private bank in Stellacure. First in Germany. China max storage is reported to be 2M stems and is a injectable manufacturer. Injectable market is to become a $140B market by 2014. IBC is a CBAI shareholder with 14M shares or $8M investment went it traded in 2006. Sanofi France is in Boston to acquire Genzyme stem repository for a reported $20B. We enjoy a Donor relationship with Osiris-Genzyme soon to become a relationship with Sanofi.
If CBAI is sitting on a mountain load of discarded stems or has devised a plan to acquire a mountain load of discarded stems then someone like Sanofi will want to buy. I posted the fact that Sanofi has an HIV vaccine that requires the autologous cord blood to make it effective. These are the facts of what is happening in the sector... we wait to see what it means and what pathway CBAI is on. Is it annuity or is it discarded cords?
Market Data 
Markets 
AI
